|
|
HOME >>
Pharmaceuticals API List 4 >>
Tazobactam
Tazobactam
Systematic (IUPAC) name
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
acid 4,4-dioxide
Identifiers
CAS number 89786-04-9
ATC code J01CG02
PubChem ?
DrugBank EXPT03012
Chemical data
Formula C10H12N4O5S
Mol. mass 300.289 g/mol
Molecular Formula C10H11N4NaO5S
Molecular Weight 322.27
Indications and Usage
Treatment of moderate to severe infections caused by -resistant /tazobactam-susceptible,
β-lactamase producing strains of microorganisms in the following conditions:
appendicitis ( complicated by rupture or abscess); uncomplicated and
complicated skin and skin structure infections; postpartum endometritis or
pelvic inflammatory disease; community-acquired pneumonia (moderate severity
only); nosocomial pneumonia (moderate to severe).
Dosage and Administration
Administer by IV infusion over 30 min.
Nosocomial Pneumonia
Adults
IV Start with 4.5 g every 6 h plus an aminoglycoside (administered
separately) for 7 to 14 days.
Healthy Renal Function (CrCl 90 mL/min or more)
Adults
IV 3.375 g every 6 h totaling 13.5 g ( 12 g/tazobactam 1.5 g) for 7 to 10
days.
Children 2 mo of age and older
IV 80 mg/tazobactam 10 mg per kg every 8 h. Children weighing more
than 40 kg with healthy renal function should receive the adult dose.
Children with appendicitis and/or peritonitis 2 mo of age and older
IV Children between 2 and 9 mo of age – 80 mg/tazobactam 10 mg per kg
every 8 h. Children 9 mo of age and older weighing up to 40 kg – 100
mg/tazobactam 12.5 mg per kg every 8 h. Children weighing more than 40 kg –
Administer the adult dose.
Renal Function Impairment
Adults
IV CrCl greater than 40 mL/min – 3.375 g every 6 h (all indications), and
4.5 g every 6 h (nosocomial pneumonia). CrCl 20 to 40 mL/min – 2.25 g every
6 h (all indications), and 3.375 g every 6 h (nosocomial pneumonia). CrCl
less than 20 mL/min – 2.25 g every 8 h (all indications), and 2.25 g every 6
h (nosocomial pneumonia). There are no dosage recommendations for children
with renal function impairment.
Hemodialysis
Adults
IV Max dosage 2.25 g every 8 h for nosocomial pneumonia and every 12 h for
other indications plus one additional dose of 0.75 g following each dialysis
period.
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Adults
IV 2.25 g every 8 h for nosocomial pneumonia and every 12 h for other
indications.
Drug Interactions
Aminoglycosides
May form microbiologically inactive complexes and should not be mixed in the
same container.
Anticoagulants/Heparin
Frequently monitor coagulation parameters.
Methotrexate
May reduce Cl of methotrexate.
Probenecid
Increases and prolongs t ½ of penicillin levels.
Vecuronium
Neuromuscular blockade may be prolonged.
Incompatibility
Ringer's lactate solution.
Patient Information
* Advise patient or caregiver that medication will be prepared by health
care provider and administered in a health care setting.
* Review dosing schedule and prescribed length of therapy with patient.
Advise patient that dose, dosing frequency, and duration of therapy are
dependent on site of infection, severity of infection, and response to
treatment.
* Advise patient or caregiver to immediately inform health care provider if
injection-site pain or redness, skin rash, hives, itching, or shortness of
breath occur during treatment.
* Advise patient or caregiver to report the following signs of
superinfection to health care provider: black “furry” tongue, foul-smelling
stools, vaginal itching or discharge, white patches in mouth.
* Warn patient or caregiver that diarrhea containing blood or pus may be a
sign of a serious disorder and, if noted after discharge, to seek medical
care and not treat at home.
PDF DOWNLOAD
WORD DOCUMENT
|
©
2004 - 2019 Taj
Pharmaceuticals Limited .
All rights reserved
India
